Raif Geha, MD

Dr. Geha is the James L. Gamble Professor of Pediatrics at Harvard Medical School and Chief of the Allergy/Immunology/Rheumatology and Dermatology Division at Children’s Hospital in Boston. His research interests are the molecular basis of primary immunodeficiencies and of atopic dermatitis. He has more than 500 published original articles, which have appeared in top journals such as Cell, Immunity, Nature, Molecular Cell or PNAS. Over the past 30 years Dr. Geha has trained more than 100 postdoctoral fellows, many of whom have risen to leadership positions in the fields of allergy and immunology.

Among the honors he has received are the Mead Johnson Award for Pediatric Research, the Kuwait Foundation for the Advancement of Sciences Prize and the American Association of Immunologists Award for Human Immunology Research.

Dr. Geha is a graduate of American University of Beirut, Lebanon, where he also completed his internship at the university’s hospital in Lebanon. He completed residency and a post-graduate fellowship at Boston Children’s Hospital.

Cox Terhorst, PhD

Dr. Terhorst is Chief of Immunology at Dana-Farber Cancer Institute and the Beth Deaconess Medical Center of Harvard University. Dr. Therhorst’s laboratory is interested in the assembly and signal transduction of the T cell receptor for antigen. They examine the role of the CD3 genes in thymocyte development and in T cell function in mice in which the CD3 genes have been eliminated by homologous recombination techniques. In addition, the mechanisms that govern expression of the three CD3 genes in early T cells are being studied.

Ted Sybertz, PhD

Ted received a PhD from the University of Minnesota and did postdoctoral research at the University of Virginia. From 1979-1998 he was employed at Schering Plough Research Institute and held positions of increasing responsibility in drug discovery and development and was appointed to the position of senior director and Presidential Fellow from 1995-1998. His research efforts contributed to the discovery of new therapies for treating cardiovascular diseases including ezetimibe, a novel and important therapy for treating hypercholesterolemia and vorapaxar, a new antithrombotic agent recently approved by the FDA. Dr. Sybertz joined GelTex Pharmaceuticals in 1998 as senior vice president of Research and Development. In 2000, GelTex merged with Genzyme Corporation. Ted served as senior vice president and general manager of Drug Discovery and Development at Genzyme until 2011. Ted now serves on the scientific advisory board of Lysosomal Therapeutics and consults with numerous biopharma companies and investors. He is a member of the American Society for Pharmacology and Therapeutics. He was chairman of the research committee and a member of the board of directors of the New Jersey chapter of the American Heart Association. Ted also served on the scientific advisory boards of Sirtris Pharmaceuticals and Syndexa Pharmaceuticals.

Steven Butcher, PhD

Dr Butcher serves as an Operating Partner of Advent Life Sciences Fund II LP.
Dr Butcher has over 20 years of experience in both small biotech and larger pharmaceutical companies. He has a strong track record in pre-clinical research and development, as well as business and corporate development. Dr. Butcher was a founder of the Fujisawa Institute of Neuroscience in 1991 and served as its Scientific Director. He joined Pharmacia and Upjohn AB in 1997 as Head of Biochemistry, and from 1998 was Director of Target Discovery for Pharmacia AB in Sweden. He joined Gemini Genomics (Cambridge, UK) in 2000 as VP Research, and then served as CSO of BioImage A/S (Denmark) from 2003 to 2006. Dr Butcher joined TopoTarget A/S (Denmark) in 2006 and served as Chief Operating Officer and VP, Corporate Development. More recently, he was Chief Operating Officer at CoCo Therapeutics Ltd. Dr. Butcher is originally a pharmacologist with a Ph.D. in Pharmacology from University of Southampton, UK.